Literature DB >> 9059358

Peptic duodenitis--does it exist in the second part of the duodenum?

N Leonard1, C F Feighery, D O Hourihane.   

Abstract

AIM: To re-evaluate all patients diagnosed histologically as having peptic duodenitis who had known endomysial antibody (EMA) test results to find out whether they would still be classified as peptic duodenitis on histological analysis and to review their subsequent clinical course.
METHODS: All mucosal biopsy specimens of the second part of the duodenum which were reported as showing features of peptic duodenitis and on which a serum EMA test had been done between January 1990 and January 1995 were reviewed. The number of intraepithelial lymphocytes (IELs) per 500 epithelial cells was also counted. The cases were re-assigned to one of three clinical categories: normal, coeliac disease or peptic duodenitis. Clinical details were reviewed for any cases where the re-assigned diagnosis and the EMA test result did not correlate.
RESULTS: Of the 24 cases, 21 showed a correlation between morphology and immunology-that is, if the biopsy specimen was characteristic of coeliac disease, the EMA was positive and if the biopsy specimen was normal or characteristic of peptic duodenitis, the EMA was negative. Three cases had a negative correlation: two had a positive EMA test but a biopsy diagnosis of peptic duodenitis and one had a normal duodenal biopsy specimen with a positive EMA test. On review of their clinical details, two of the three patients were diagnosed with coeliac disease and the other with silent coeliac disease. EMA test results and IEL counts correlated with the final diagnosis in all cases.
CONCLUSIONS: The diagnosis of peptic duodenitis on biopsy specimens of the second part of the duodenum was not substantiated in 92% of cases. On review of 24 cases, a histological diagnosis of peptic duodenitis was reached in four. In difficult cases, the histological appearances should be correlated with the EMA test result and the IEL count. Correlation of this kind should leave no cases of coeliac disease undiagnosed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9059358      PMCID: PMC499714          DOI: 10.1136/jcp.50.1.54

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  6 in total

1.  Morphology of the gastric mucosa in patients with ulcer diseases.

Authors:  J S Trier
Journal:  Am J Dig Dis       Date:  1976-02

2.  Gastric and duodenal mucosa in 'healthy' individuals. An endoscopic and histopathological study of 50 volunteers.

Authors:  J Kreuning; F T Bosman; G Kuiper; A M Wal; J Lindeman
Journal:  J Clin Pathol       Date:  1978-01       Impact factor: 3.411

Review 3.  Clinical and pathological spectrum of coeliac disease--active, silent, latent, potential.

Authors:  A Ferguson; E Arranz; S O'Mahony
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

4.  Intestinal ulceration--a complication of celiac disease.

Authors:  T M Bayless; R F Kapelowitz; W M Shelley; W F Ballinger; T R Hendrix
Journal:  N Engl J Med       Date:  1967-05-04       Impact factor: 91.245

5.  Comparison of IgA-class reticulin and endomysium antibodies in coeliac disease and dermatitis herpetiformis.

Authors:  O Hällström
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

6.  Coeliac disease with histological features of peptic duodenitis: value of assessment of intraepithelial lymphocytes.

Authors:  M D Jeffers; D O Hourihane
Journal:  J Clin Pathol       Date:  1993-05       Impact factor: 3.411

  6 in total
  2 in total

Review 1.  Biopsy assessment of drug efficacy in the gastrointestinal tract.

Authors:  Marjorie M Walker
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

2.  Identification of distinctive clinical significance in hospitalized patients with endoscopic duodenal mucosal lesions.

Authors:  Yeji Han; Hye-Kyung Jung; Ji Young Chang; Chang Mo Moon; Seong-Eun Kim; Ki-Nam Shim; Sung-Ae Jung; Joo-Young Kim; Ji-Yun Bae; Sae-In Kim; Ji-Hyun Lee; Sanghui Park
Journal:  Korean J Intern Med       Date:  2017-08-21       Impact factor: 2.884

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.